Figure 1 | Scientific Reports

Figure 1

From: Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy

Figure 1

A2/NY-ESO-1157-specific CAR redirects peripheral blood T cells. (a) Second generation CAR possessing an A2/NY-ESO-1157-specific scFv (clone 3M4E5) followed by a transmembrane domain of CD28 and a cytoplasmic domain of CD3ζ was generated. (b) The A2/NY-ESO-1157-specific CAR was transduced into peripheral blood T cells. These CAR-T cells were stained with 5 μg/mL A2/NY-ESO-1157 tetramer or A2/HIV Gag77 tetramer. Representative staining of A2/NY-ESO-1157 CAR-CD8+ T cells (left) and CD4+ T cells (right) obtained from donor 1 is shown. (c) A2/NY-ESO-1157 CAR-CD8+ T cells (left) and CD4+ T cells (right) derived from 5 out of 5 donors were reproducibly stained with A2/NY-ESO-1157 tetramer. (d) A2/NY-ESO-1157 CAR-CD8+ T cells (left) and CD4+ T cells (right) established from donor 1 were cocultured with T2 cells loaded with 10 μg/mL NY-ESO-1157 peptide or HIV Gag77 peptide. The experiments were performed in triplicate and error bars show the SD. *P < 0.05; ***P < 0.001; ****P < 0.0001; n.s., not significant. ΔNGFR-positive cells were gated and analyzed.

Back to article page